Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it appointed two new members to its board of directors.
Thomas Forest Farb-Horch and Agnieszka Winkler joined Dublin, Ohio-based Navidea’s board, effective Oct. 7, each with a three-year term ending concurrently with the company’s 2024 annual stockholders meeting.
According to a news release, Farb-Horch, a veteran of over three decades as an investor and senior executive in the life science and information technology sectors, has served as CEO, president, co-founder and director of Thrive Bioscience. Farb-Horch held other executive positions at Interneuron Pharmaceuticals, Indevus Pharmaceuticals and Cytyc.
Winkler serves on the board of directors of Virco and the board of trustees at both Santa Clara University and the African Diaspora Network. She’s previously served on the board at public companies across multiple disciplines, including SuperCuts, Reno Air, The Cheesecake Factory and Inter-Tel. Winkler was also the founder, chair and CEO of TeamToolz and Winkler Advertising, both of which were acquired.
Navidea’s board has undergone a recent personnel shift, as less than a month after its chair of the board and director S. Kathryn Rouan, along with director Claudine Bruck, retired from those positions. The board appointed Alexander L. Cappello and John K. Scott, Jr., both existing members of the board, as the chair and vice chair of the board, respectively.
“Navidea is pleased to add two highly respected and exceptionally talented individuals to its board of directors,” Navidea CEO Jed Latkin said in the release. “Their combined experience will help guide the company through its next phases of growth and development.”
Navidea develops precision immunodiagnostic agents and immunotherapeutics, including dextran-based drug delivery vehicles that deliver potent drugs to the cells where the virus is multiplying, targeting specific macrophages that replicate.
